| 产品名称： | MAT-Ly-Lu-B-2 MLLB-2 |
|---|---|
| 商品货号： | TS211530 |
| Organism： | Rattus norvegicus, rat |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | malignant carcinoma |
| Age： | 22 months |
| Gender： | male |
| Strain： | Copenhagen |
| Applications： | MAT-LyLu was derived from a adult malignant rat prostate tumor obtained from a 22 month old inbred Copenhagen rat by Isaacs et al. They are more resistant to vinblastine compared to controls. These cells express a multidrug (MDR) resistant phenotype. This cell line can be used to study chemotherapy resistance in prostate cancer. |
| Derivation： | MAT-Ly-Lu-B-2 was developed from the MAT-LyLu cell line (ATCC JHU-92). MAT-LyLu was derived from a adult malignant rat prostate tumor obtained from a 22 month old inbred Copenhagen rat by Isaacs et al. |
| Clinical Data： | This cell line can be used to study chemotherapy resistance in prostate cancer. male |
| Comments： | MAT-Ly-Lu-B-2 was developed from the MAT-LyLu cell line (ATCC JHU-92). MAT-LyLu was derived from a adult malignant rat prostate tumor obtained from a 22 month old inbred Copenhagen rat by Isaacs et al. The parental cells were grown in increasing concentrations of the drug doxorubicin until the final concentration of 0.001 mM was achieved. These cells express a multidrug (MDR) resistant phenotype. They are more resistant to vinblastine compared to controls. This cell line can be used to study chemotherapy resistance in prostate cancer. |
| Complete Growth Medium： | RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.001 mM doxorubicin, 90%; fetal bovine serum, 10%
|
| Subculturing： | Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended Medium Renewal: Every 2 to 3 days Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Name of Depositor： | KJ Pienta |
| Deposited As： | rat |
| References： | Isaacs JT, et al. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281, 1986. PubMed: 3774632 Replogle-Schwab TS, et al. Development of doxorubicin resistant rat prostate cancer cell lines. Anticancer Res. 17: 4535-4538, 1997. PubMed: 9494564 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | MAT-Ly-Lu-B-2 MLLB-2 |
|---|---|
| 商品货号： | TS211530 |
| Organism： | Rattus norvegicus, rat |
| Product Format： | frozen |
| Morphology： | epithelial |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | malignant carcinoma |
| Age： | 22 months |
| Gender： | male |
| Strain： | Copenhagen |
| Applications： | MAT-LyLu was derived from a adult malignant rat prostate tumor obtained from a 22 month old inbred Copenhagen rat by Isaacs et al. They are more resistant to vinblastine compared to controls. These cells express a multidrug (MDR) resistant phenotype. This cell line can be used to study chemotherapy resistance in prostate cancer. |
| Derivation： | MAT-Ly-Lu-B-2 was developed from the MAT-LyLu cell line (ATCC JHU-92). MAT-LyLu was derived from a adult malignant rat prostate tumor obtained from a 22 month old inbred Copenhagen rat by Isaacs et al. |
| Clinical Data： | This cell line can be used to study chemotherapy resistance in prostate cancer. male |
| Comments： | MAT-Ly-Lu-B-2 was developed from the MAT-LyLu cell line (ATCC JHU-92). MAT-LyLu was derived from a adult malignant rat prostate tumor obtained from a 22 month old inbred Copenhagen rat by Isaacs et al. The parental cells were grown in increasing concentrations of the drug doxorubicin until the final concentration of 0.001 mM was achieved. These cells express a multidrug (MDR) resistant phenotype. They are more resistant to vinblastine compared to controls. This cell line can be used to study chemotherapy resistance in prostate cancer. |
| Complete Growth Medium： | RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.001 mM doxorubicin, 90%; fetal bovine serum, 10%
|
| Subculturing： | Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended Medium Renewal: Every 2 to 3 days Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Name of Depositor： | KJ Pienta |
| Deposited As： | rat |
| References： | Isaacs JT, et al. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281, 1986. PubMed: 3774632 Replogle-Schwab TS, et al. Development of doxorubicin resistant rat prostate cancer cell lines. Anticancer Res. 17: 4535-4538, 1997. PubMed: 9494564 |
